NDRA · ENDRA Life Sciences Inc

-

Please sign in to comment on NDRA

1 Comment

Admin

4 years ago

ENDRA Life Sciences Inc is currently in a long term uptrend where the price is trading 19.3% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

ENDRA Life Sciences Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 53.2% to $-2M since the same quarter in the previous year.

Finally, its free cash flow fell by 9.9% to $-2M since the same quarter in the previous year.

Based on the above factors, ENDRA Life Sciences Inc gets an overall score of 3/5.

Sector	Healthcare
Industry	Diagnostics & Research
Exchange	NASDAQ
CurrencyCode	USD
ISIN	US29273B1044

Market Cap	2M
PE Ratio	None
Target Price	50
Beta	0.19
Dividend Yield	None

ABOUT

ENDRA Life Sciences Inc

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

NDRA · ENDRA Life Sciences Inc

-

ENDRA Life Sciences Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest ENDRA Life Sciences Inc using a moving average strategy